Teva Pharmaceutical Industries (NYSE:TEVA) Downgraded by UBS Group

Teva Pharmaceutical Industries (NYSE:TEVA) was downgraded by equities researchers at UBS Group from a “buy” rating to a “neutral” rating in a research note issued to investors on Tuesday, reports. They currently have a $11.00 price objective on the stock, down from their previous price objective of $15.00. UBS Group’s price target points to a potential upside of 1.76% from the stock’s current price.

TEVA has been the subject of several other research reports. TheStreet raised Teva Pharmaceutical Industries from a “d+” rating to a “c-” rating in a research report on Monday, April 5th. JPMorgan Chase & Co. reissued a “hold” rating and set a $10.00 price target on shares of Teva Pharmaceutical Industries in a research report on Sunday, March 14th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and three have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $11.58.

Shares of NYSE:TEVA opened at $10.81 on Tuesday. The company has a current ratio of 1.00, a quick ratio of 0.63 and a debt-to-equity ratio of 2.22. The company has a market cap of $11.81 billion, a price-to-earnings ratio of -2.94, a price-to-earnings-growth ratio of 0.87 and a beta of 1.49. Teva Pharmaceutical Industries has a 12 month low of $8.44 and a 12 month high of $13.30. The company has a 50-day moving average price of $11.02 and a 200-day moving average price of $10.61.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, April 28th. The company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.55 by $0.08. Teva Pharmaceutical Industries had a positive return on equity of 19.32% and a negative net margin of 24.17%. The business had revenue of $3.98 billion during the quarter, compared to analysts’ expectations of $4.04 billion. During the same quarter last year, the business posted $0.76 EPS. The business’s revenue was down 8.6% on a year-over-year basis. As a group, research analysts forecast that Teva Pharmaceutical Industries will post 2.42 EPS for the current fiscal year.

In related news, insider Mark Sabag sold 127,244 shares of Teva Pharmaceutical Industries stock in a transaction on Tuesday, March 16th. The stock was sold at an average price of $11.22, for a total value of $1,427,677.68. Following the completion of the sale, the insider now owns 20,598 shares of the company’s stock, valued at $231,109.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.56% of the company’s stock.

Large investors have recently modified their holdings of the company. Ayalon Holdings Ltd. purchased a new position in shares of Teva Pharmaceutical Industries during the 1st quarter worth $26,000. Jeppson Wealth Management LLC bought a new stake in Teva Pharmaceutical Industries during the 3rd quarter worth approximately $26,000. Freedman Financial Associates Inc. purchased a new position in Teva Pharmaceutical Industries during the fourth quarter valued at approximately $38,000. Safeguard Investment Advisory Group LLC bought a new position in Teva Pharmaceutical Industries in the 4th quarter worth approximately $42,000. Finally, Wealthcare Advisory Partners LLC purchased a new stake in Teva Pharmaceutical Industries during the 1st quarter valued at approximately $57,000. Hedge funds and other institutional investors own 51.20% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Featured Article: Investing strategies using the yield curve

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with's FREE daily email newsletter.